Advertisement
CLNN vs KZIA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLNN is a Buy and KZIA is a StrongBuy.
CLNN's RSI Indicator climbs out of oversold territory
The RSI Indicator for CLNN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In 42 of the 45 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CLNN as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CLNN just turned positive on October 21, 2026. Looking at past instances where CLNN's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +4.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLNN advanced for three days, in 193 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CLNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CLNN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CLNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.226) is normal, around the industry mean (1.728). P/E Ratio (-1.093) is within average values for comparable stocks, (6.556). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. CLNN's P/S Ratio (222.222) is very high in comparison to the industry average of (4.925).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
KZIA's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for KZIA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In 42 of the 45 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 60 cases where KZIA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for KZIA just turned positive on October 21, 2026. Looking at past instances where KZIA's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where KZIA advanced for three days, in 196 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
KZIA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KZIA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KZIA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. KZIA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.833) is normal, around the industry mean (2.973). P/E Ratio (-0.159) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KZIA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLNN | KZIA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 84 | 65 | |
P/E GROWTH RATING 1..100 | 15 | 13 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KZIA's Valuation (81) in the Biotechnology industry is in the same range as CLNN (94) in the null industry. This means that KZIA’s stock grew similarly to CLNN’s over the last 12 months.
KZIA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLNN (100) in the null industry. This means that KZIA’s stock grew similarly to CLNN’s over the last 12 months.
KZIA's SMR Rating (100) in the Biotechnology industry is in the same range as CLNN (100) in the null industry. This means that KZIA’s stock grew similarly to CLNN’s over the last 12 months.
KZIA's Price Growth Rating (65) in the Biotechnology industry is in the same range as CLNN (84) in the null industry. This means that KZIA’s stock grew similarly to CLNN’s over the last 12 months.
KZIA's P/E Growth Rating (13) in the Biotechnology industry is in the same range as CLNN (15) in the null industry. This means that KZIA’s stock grew similarly to CLNN’s over the last 12 months.
| CLNN | KZIA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 85% | N/A |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 83% | 2 days ago 82% |
| Declines ODDS (%) | 7 days ago 90% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLNN’s FA Score shows that 1 FA rating(s) are green while KZIA’s FA Score has 1 green FA rating(s).
- CLNN’s FA Score: 1 green, 4 red.
- KZIA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLNN’s TA Score shows that 5 TA indicator(s) are bullish while KZIA’s TA Score has 5 bullish TA indicator(s).
- CLNN’s TA Score: 5 bullish, 3 bearish.
- KZIA’s TA Score: 5 bullish, 2 bearish.
Price Growth
CLNN (@Food: Major Diversified) experienced а +17.40% price change this week, while KZIA (@Biotechnology) price change was +9.05% for the same time period.
The average weekly price growth across all stocks in the @Food: Major Diversified industry was -1.90%. For the same industry, the average monthly price growth was -8.95%, and the average quarterly price growth was -18.27%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
CLNN is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Food: Major Diversified (-1.90% weekly)Companies in this industry usually make a diverse range of agricultural and/or processed food. Some prominent names in this segment are Mondelez International, which makes chocolates, biscuits, cookies etc. The Kraft Heinz Company specializes in ketchups, sauces, fruit drink pouches and many more. General Mills, Inc. sells flour and cereal. Kellogg is famous for its snacks and breakfast cereal. And so on down the line. As more and more consumers are looking for healthier options in food in recent years, several legacy food companies have responded by revamping brands to include organic and no-added-sugar versions, and/or acquiring healthy food firms, and even streamlining operations.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KZIA and
Correlation & Price change
A.I.dvisor tells us that KZIA and CLNN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KZIA and CLNN's prices will move in lockstep.
| Ticker / NAME | Correlation To KZIA | 1D Price Change % | ||
|---|---|---|---|---|
| KZIA | 100% | -1.34% | ||
| CLNN - KZIA | 33% Poorly correlated | +3.19% | ||
| ANNX - KZIA | 31% Poorly correlated | -1.30% | ||
| LGVN - KZIA | 30% Poorly correlated | +11.19% | ||
| RVMD - KZIA | 29% Poorly correlated | -3.39% | ||
| PMCB - KZIA | 29% Poorly correlated | +1.89% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBTK | 19.17 | 0.11 | +0.58% |
| iShares iBonds Dec 2030 Term Treasury ETF (IBTK) | |||
| APXM | 32.21 | N/A | N/A |
| FT Vest U.S. Equity Max Buffer ETF - April (APXM) | |||
| IFLO | 36.04 | -0.07 | -0.19% |
| VictoryShares International Free Cash Flow ETF (IFLO) | |||
| PTBD | 18.28 | -0.06 | -0.33% |
| Pacer Trendpilot US Bond ETF (PTBD) | |||
| SSS | 22.71 | -0.46 | -2.00% |
| CYBER HORNET S&P 500 and Solana 75/25 Strategy ETF (SSS) | |||